Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Integrated incremental immunoreactive insulin and connecting peptide responses to an oral glucose load of 50 g and an "isoglycaemic" intravenous glucose infusion, respectively, were measured in 14 Type 2 (non-insulin-dependent) diabetic patients and 8 age- and weight-matched metabolically healthy control subjects. Differences between responses to oral and intravenous glucose administration are attributed to factors other than glucose itself (incretin effect). Despite higher glucose increases, immunoreactive insulin and connecting peptide responses after oral glucose were delayed in diabetic patients. Integrated responses were not significantly different between both groups. However, during "isoglycaemic" intravenous infusion, insulin and connecting peptide responses were greater in diabetic patients than in control subjects as a consequence of the higher glycaemic stimulus. The contribution of incretin factors to total insulin responses was 72.8 +/- 6.9% (100% = response to oral load) in control subjects and 36.0 +/- 8.8% in diabetic patients (p less than or equal to 0.05). The contribution to connecting peptide responses was 58.4 +/- 7.6% in control subjects and 7.6 +/- 14.5% (p less than or equal to 0.05) in diabetic patients. Ratios of integrated insulin to connecting peptide responses suggest a reduced (hepatic) insulin extraction in control subjects after oral as compared to intravenous glucose. This was not the case in diabetic patients. Immunoreactive gastric inhibitory polypeptide responses were not different between control subjects and diabetic patients.(ABSTRACT TRUNCATED AT 250 WORDS)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is well-known that the incretin effect is weakened or no longer present in subjects with T2D, albeit more or less normal secretion of GIP e GLP-1 [16,17,18].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [16]
Experimental — accuracy not yet measuredIn the citing paper
“People with obesity and/or T2D have impaired incretin release ( Toft-Nielsen et al., 2001 ; Vilsbøll et al., 2001 ) and/or function ( Nauck et al., 1986 ; Muscelli et al., 2008 )”
From Pharmacologic inhibition of somatostatin receptor 2 to restore glucagon counterregulation in diabetes (2024) · cites this paper as Nauck et al., 1986
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
National Diabetes Data Group (1979) · Diabetes · doi:10.2337/diab.28.12.1039 · Cited by 4,909
Plasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*
Perley, M. J., & Kipnis, D. M. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105685 · Cited by 917 · cited 2×
“Thus the study of Perley and Kipnis [ 10 ] from 1967 does not - in the absence of C-peptide measurements - allow final conclusions about the incretin effect in Type 2 diabetic patients.”
BackgroundSeltzer, H. S., Allen, E. W., Herron, A. L., & Brennan, M. T. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105534 · Cited by 883
NAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874 · cited 5×
“In healthy young subjects, a clear dose-dependency of incretin effects after oral glucose has been observed [6].”
BackgroundResultInfluentialSelf-citationRadioimmunological determination of human C-peptide in serum
Heding, L. G. (1975) · Diabetologia · doi:10.1007/bf01222104 · Cited by 830
Creutzfeldt, W. (1979) · Diabetologia · doi:10.1007/bf01225454 · Cited by 731 · cited 1×
“Insulin secretion after an oral glucose load is due to stimulation of the pancreatic B cell by elevation of the plasma glucose level and, in addition, by incretin factors (gastrointestinal hormones and possibly nerves) which potentiate the secretory response to hyperglycaemia alone [1, 2].”
BackgroundSelf-citationThe Effect of Insulin Treatment on Insulin Secretion and Insulin Action in Type II Diabetes Mellitus
Garvey, W. T., Olefsky, J. M., Griffin, J., Hamman, R. F., & Kolterman, O. G. (1985) · Diabetes · doi:10.2337/diab.34.3.222 · Cited by 488 · cited 1×
“Arguing against this explanation, intravenous isoproterenol [36] or glucagon [ 37 ] enhanced, rather than diminished, additional B cell secretory responses in Type 2 diabetic patients when plasma glucose levels had been elevated by glucose infusion up to the range employed in our study.”
ResultC-Peptide as a Measure of the Secretion and Hepatic Extraction of Insulin: Pitfalls and Limitations
Polonsky, K. S., & Rubenstein, A. H. (1984) · Diabetes · doi:10.2337/diab.33.5.486 · Cited by 476 · cited 3×
“This conclusion must, however, remain speculative because of reservations regarding the "insulin to C-peptide ratio method" for estimating changes in (hepatic) insulin extraction [ 33 ].”
BackgroundMethodInfluentialTHE PLASMA INSULIN RESPONSE TO GLUCOSE INFUSION IN HEALTHY SUBJECTS AND IN DIABETES MELLITUS
Cerasi, E., & Luft, R. (1967) · Acta Endocrinologica · doi:10.1530/acta.0.0550278 · Cited by 371 · cited 2×
“The markedly reduced incretin effect found in our group with a more severe degree of Type 2 diabetes may simply be an expression of their impaired capacity to secrete insulin at an adequate rate [3, 4 ]. The glycaemic stimulus with plasma glucose values of -17mmol/1 (300mg/dl) may already have led to maximal B cell st…”
BackgroundUnger, R. H. (1969) · Archives of Internal Medicine · doi:10.1001/archinte.1969.00300130043007 · Cited by 371 · cited 1×
“Insulin secretion after an oral glucose load is due to stimulation of the pancreatic B cell by elevation of the plasma glucose level and, in addition, by incretin factors (gastrointestinal hormones and possibly nerves) which potentiate the secretory response to hyperglycaemia alone [1, 2 ].”
Background
Research works printed but not linked: 4
- Bloom SR (1975) GIP in diabetes (abstract). Diabetologia 11: 334
- WHO Expert Committee on Diabetes Mellitus, Second Report, Technical Report Series 646, WHO, Geneva, 1980
- Madison LL, Kaplan N (1958) The hepatic binding of I-131 labeled insulin in human subjects during a single transhepatic circulation. J Lab Clin Med 52: 927–932
- Ross SA, Brown JC, Dupre J (1974) Effects of Gastric Inhibitory Polypeptide on endocrine pancreas in normal and diabetic subjects. Diabetologia 10: 384 (Abstract)
Cited by
Items 501–600 of 1,001
Gluco-metabolic effects of oral and intravenous alcohol administration in men
Lanng, A. R., Gasbjerg, L. S., Bergmann, N. C., Bergmann, S., Helsted, M. M., Gillum, M. P., Hartmann, B., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2019) · Endocrine Connections · doi:10.1530/ec-19-0317 · Cited by 32
Clinical Measures of Islet Function: Usefulness to Characterize Defects in Diabetes
Åhrén, B., Pratley, R. E., Soubt, M., Dunning, B. E., & Foley, J. E. (2008) · Current Diabetes Reviews · doi:10.2174/157339908784220714 · Cited by 32
Gastric stimulation for weight loss
Mizrahi, M., Yaʼacov, A. B., & Ilan, Y. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i19.2309 · Cited by 35
The incretin effect in critically ill patients: a case–control study
Nielsen, S. T., Janum, S., Krogh‐Madsen, R., Solomon, T. P. J., & Møller, K. (2015) · Critical Care · doi:10.1186/s13054-015-1118-z · Cited by 31
“The incretin effect was calculated as incretin effect = [incremental area under the curve (iAUC) insulin OGTT − iAUC insulin IVGI]/iAUC insulin OGTT [8].”
MethodLee, Y. S., Riopel, M., Cabrales, P., & Bandyopadhyay, G. K. (2019) · Science Advances · doi:10.1126/sciadv.aaw4176 · Cited by 33
“In healthy humans, incretin action is responsible for approximately 60 to 70% of postprandial insulin secretion ( 6 ).”
Pharmacotherapy of Diabetes: New Developments
Mogensen, C. E. (2007) · Springer eBooks · doi:10.1007/978-0-387-69737-6 · Cited by 37
Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
Campbell, R. K., & Neumiller, J. J. (2010) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s7314 · Cited by 30
Tucker, A. J., Vandermey, J., Robinson, L. E., Graham, T. E., Bakovic, M., & Duncan, A. M. (2013) · Journal of Functional Foods · doi:10.1016/j.jff.2013.09.025 · Cited by 34
Ileal interposition with sleeve gastrectomy for treatment of type 2 diabetes mellitus
Kota, S., Ugale, S. M., Gupta, N., Naik, V., Kumar, K. V. S. H., & Modi, K. D. (2012) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.98017 · Cited by 32
“Tinoco et al. have demonstrated that pre-surgical BMI and duration of T2DM were not the determinant factors for the post-surgical remission of T2DM.”
BackgroundInfluentialEffects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes
Miyagawa, K., Kondo, T., Goto, R., Matsuyama, R., Ono, K., Kitano, S., Kawasaki, S., Igata, M., Kawashima, J., Matsumura, T., et al. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-160 · Cited by 32
“Because the action of incretin is attenuated in type 2 diabetics [4], exogenous GLP-1 administration improves glycemic control [5].”
BackgroundTriplitt, C. L., Solis‐Herrera, C., Cersósimo, E., Abdul‐Ghani, M. A., & DeFronzo, R. A. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1114098 · Cited by 33
Chou, W.-L. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105693 · Cited by 32
New Aspects of Diabetes Research and Therapeutic Development
Satin, L. S., Soleimanpour, S. A., & Walker, E. M. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000160 · Cited by 34
Tahara, A., Matsuyama‐Yokono, A., Nakano, R., Someya, Y., Hayakawa, M., & Shibasaki, M. (2009) · Pharmacological Reports · doi:10.1016/s1734-1140(09)70147-1 · Cited by 30
“In healthy subjects, the insulinotropic effect of GLP-1 accounts for 50 to 70% of the insulin response to an oral glucose load, but the associated “incretin effect” is often markedly reduced in type 2 diabetic patients [14].”
BackgroundPuddu, A., Mach, F., Nencioni, A., Viviani, G. L., & Montecucco, F. (2013) · Mediators of Inflammation · doi:10.1155/2013/591056 · Cited by 35
Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes
Schnabel, C. A., Wintle, M. E., & Kolterman, O. (2006) · Vascular Health and Risk Management · doi:10.2147/vhrm.2006.2.1.69 · Cited by 32
“Partly due to reduced postprandial secretion of GLP-1, patients with type 2 diabetes exhibit an impaired incretin response compared with individuals with normal glucose tolerance (Nauck et al 1986; Toft-Nielsen et al 2001).”
BackgroundGLP-1 receptor agonists: Targeting both hyperglycaemia and disease processes in diabetes
Holst, J. J., & Seino, Y. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.02.017 · Cited by 33
Physiology of Glucose Homeostasis and Insulin Therapy in Type 1 and Type 2 Diabetes
Ferrannini, E. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.01.003 · Cited by 34
Gribble, F. M. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02514.x · Cited by 32
Gut peptides in the treatment of diabetes mellitus
Vahl, T. P., & D’Alessio, D. A. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.3.177 · Cited by 31
“Interestingly, Type 2 diabetic subjects display a drastic reduction in the incretin effect [19], which may contribute to the inadequate postprandial insulin secretion.”
BackgroundIncretins and their role in the management of diabetes
Frías, J. P., & Edelman, S. V. (2007) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32825ea2ba · Cited by 30
Ikushima, I., Jensen, L., Flint, A., Nishida, T., Zacho, J., & Irie, S. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0677-1 · Cited by 28
An Update in Incretin-Based Therapy: A Focus on Glucagon-Like Peptide-1 Receptor Agonists
Edwards, K. L., Stapleton, M., Weis, J., & Irons, B. K. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0098.edw · Cited by 32
Incretin therapy for diabetes mellitus type 2
Holst, J. J. (2019) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000516 · Cited by 32
“The GLP-1 receptor agonists are potent antidiabetic agents, and when it comes to T2DM, they often perform significantly better than insulin.”
BackgroundInfluentialTirzepatide: A Promising Drug for Type 2 Diabetes and Beyond
Dutta, P., Kumar, Y., Babu, A. T., Ravindran, S. G., Salam, A., Rai, B., Baskar, A., Dhawan, A., & Jomy, M. (2023) · Cureus · doi:10.7759/cureus.38379 · Cited by 46
“The dietarystimulated levels of GLP-1 are reduced in T2DM, whereas the insulinotropic effects after infusion of pharmacological levels of GLP-1 are similar in people with diabetes and those who are euglycemic [17,18].”
BackgroundEdholm, T., Čejvan, K., Abdel‐Halim, S. M., Efendić, S., Schmidt, P., & Hellström, P. M. (2008) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2008.01229.x · Cited by 33
Taylor, D. R., Alaghband‐Zadeh, J., Cross, G. F., Omar, S., le Roux, C. W., & Vincent, R. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093540 · Cited by 31
“Post-prandial release of the incretin GLP-1 is impaired in type 2 diabetes mellitus [38], and HbA1c inversely correlates with maximal GLP-1 release [39]; suggesting that poorer glycaemic control is associated with a greater defect in incretin function.”
BackgroundShao, S., Liu, Z., Yang, Y., Zhang, M., & Yu, X. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22750 · Cited by 31
“…glucose transport through glucose transporter-2 (Glut2), glucose metabolism with glucokinase (GCK) involved, increased ATP/ADP ratio, membrane depolarization, and the resultant insulin granules exocytosis [Bruning et al., 1997; Lauro et al., 1998; Rorsman and Renstrom, 2003; Petersen et al., 2004].”
BackgroundJiang, J., Zhang, J., Jacobsen, L. V., & Hu, P. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010389468 · Cited by 28
Ruan, J., Meng, H., Wang, X., Chen, W., Tian, X., & Meng, F. (2020) · Cardiology Research and Practice · doi:10.1155/2020/3108124 · Cited by 28
“In type 2 diabetes mellitus, the effect of incretin decreased [17,18], and the morbidity and Table 3: Baseline data (which showed differences between the test and the control groups).”
BackgroundBeyond Glycemic Control: Treating the Entire Type 2 Diabetes Disorder
Brunton, S. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.09.2054 · Cited by 37
“The impaired function of the incretin system is a characteristic of type 2 diabetes.(30,43,44) Fasting GLP-1 lev-”
BackgroundThe interplay of glucose-dependent insulinotropic polypeptide in adipose tissue
Kagdi, S., Lyons, S. A., & Beaudry, J. L. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0361 · Cited by 33
“…dosing typically conducted in cell culture models that report changes in lipid flux within the adipocytes would be defined in the pharmacological range, as post prandial GIP levels are found to be ~400– 600 pg/mL in rodents (Campbell et al. 2016) and ~1000– 1500 pg/mL in humans (Nauck et al. 1986).”
BackgroundYamanouchi, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010027 · Cited by 40
“A hallmark of T2DM is a significantly reduced incretin effect, meaning that oral glucose fails to elicit the robust insulin response seen in healthy individuals [27].”
Gejl, M., Rungby, J., Brock, B., & Gjedde, A. (2014) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12240 · Cited by 27
Gyldenløve, M., Vilsbøll, T., Zachariae, C. O. C., Holst, J. J., Knop, F. K., & Skov, L. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12388 · Cited by 28
Mori, Y., Taniguchi, Y., Matsuura, K., Sezaki, K., Yokoyama, J., & Utsunomiya, K. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0025 · Cited by 29
“11 In this study, the average 24-h blood glucose level was decreased by sitagliptin, and this effect was mainly due to improvement of postprandial hyperglycemia.”
The physiology and pharmacology of incretins in type 2 diabetes mellitus
Holst, J. J. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00920.x · Cited by 28
KCNQ1 gene polymorphism is associated with glycaemic response to treatment with DPP-4 inhibitors
Gotthardová, I., Javorský, M., Klimčáková, L., Kvapil, M., Schroner, Z., Kozárová, M., Malachovská, Z., Ürgeová, A., Židzik, J., & Tkáč, I. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.05.018 · Cited by 27
Glucagon-Like Peptide 1: A Predictor of Type 2 Diabetes?
Larsen, M. P., & Torekov, S. S. (2017) · Journal of Diabetes Research · doi:10.1155/2017/7583506 · Cited by 28
“In patients with type 2 diabetes, the incretin effect is impaired [4].”
BackgroundSchrezenmeir, J., Tatò, F., Tato, S., Küstner, E., Krause, U., Hommel, G., Asp, N. ‐., Kasper, H., & Beyer, J. (1989) · Journal of Molecular Medicine · doi:10.1007/bf01716062 · Cited by 29
“The insulinotropic effect of GIP has been shown to be less pronounced in type-2 diabetics [15, 38 , 44].”
BackgroundTrahair, L. G., Horowitz, M., Marathe, C. S., Lange, K., Standfield, S., Rayner, C. K., & Jones, K. L. (2014) · Physiological Reports · doi:10.14814/phy2.12204 · Cited by 22
“The incretin hormones, GLP-1 and glucose-dependent insulinotropic peptide (GIP), modulate the glycemic response to oral carbohydrate (Nauck et al. 1986) and their secretion may be influenced by the rate of GE (Pilichiewicz et al. 2007).”
Backgroundvan Genugten, R. E., van Raalte, D. H., & Diamant, M. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(09)70006-3 · Cited by 27
Alogliptin benzoate for the treatment of type 2 diabetes
Rendell, M., Drincic, A., & Andukuri, R. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.656088 · Cited by 27
“Postprandial GLP-1 release is about 25 -- 30% lower in patients with type 2 diabetes and those with impaired glucose tolerance [14].”
BackgroundNatalicchio, A., Biondi, G., Marrano, N., Labarbuta, R., Tortosa, F., Spagnuolo, R., D’Oria, R., Carchia, E., Leonardini, A., Cignarelli, A., et al. (2016) · Endocrinology · doi:10.1210/en.2015-2003 · Cited by 32
Intestinal Gpr17 deficiency improves glucose metabolism by promoting GLP-1 secretion
Yan, S., Conley, J. M., Reilly, A. M., Stull, N. D., Abhyankar, S. D., Ericsson, A. C., Kono, T., Molosh, A. I., Kubal, C. A., Evans‐Molina, C., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2021.110179 · Cited by 28
Foghsgaard, S., Vedtofte, L., Andersen, E. S., Bahne, E., Andreasen, C. H., Sørensen, A. L., Forman, J. L., Mathiesen, E. R., Svare, J., Clausen, T. D., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15306 · Cited by 28
A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes
Montanya, E. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.692777 · Cited by 27
“Some patients with long-standing T2D seem to have reduced levels of GLP-1 [10-13], although this does not seem to be a universal observation among all T2D patients [14].”
BackgroundNonalcoholic Fatty Liver Disease and Type 2 Diabetes in Obese Children
Hecht, L., & Weiss, R. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0448-y · Cited by 27
“Diabetes is considered by some as a condition with reduced incretin secretion while others have suggested that some resistance exists to the incretin effect in ß cells [44].”
BackgroundSynthesis of New DPP-4 Inhibitors Based on a Novel Tricyclic Scaffold
Schwehm, C., Li, J., Song, H., Hu, X., Kellam, B., & Stocks, M. J. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500503n · Cited by 26
Drugs on the Horizon for Treatment of Type 2 Diabetes
Rachman, J., & Turner, R. C. (1995) · Diabetic Medicine · doi:10.1111/j.1464-5491.1995.tb00526.x · Cited by 30
Mechanisms for the metabolic success of bariatric surgery
Sandoval, D. A. (2019) · Journal of Neuroendocrinology · doi:10.1111/jne.12708 · Cited by 27
Role and mechanism(s) of incretin-dependent therapies for treating diabetes mellitus
Nasr, N. E., & Sadek, K. M. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-18534-2 · Cited by 32
2. DPPIV Inhibition: Promising Therapy for the Treatment of Type 2 Diabetes
Wiedeman, P. E. (2007) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(06)45502-8 · Cited by 28
Pais, R., Zietek, T., Hauner, H., Daniel, H., & Skurk, T. (2014) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00329.2013 · Cited by 26
“While RANTES levels are elevated in human type 1 and type 2 diabetes (33, 34), GLP-1 concentrations are reduced (31, 46), but no interaction between the two proteins has been described.”
BackgroundUrbano, F., Filippello, A., Pino, A. D., Barbagallo, D., Mauro, S. D., Pappalardo, A., Rabuazzo, A. M., Purrello, M., Purrello, F., & Piro, S. (2016) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00148.2015 · Cited by 25
Bonora, E., & CIGOLINI, M. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.03.002 · Cited by 26
“levels are lower than normal in T2DM [53], and this un-”
BackgroundDoğruel, H., & Balcı, M. K. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i8.446 · Cited by 28
Hegelund-Myrbäck, T., Prothon, S., Edman, K., Leander, J., Hashemi, M., Dearman, M. S., Edenro, G., Svanberg, P., Andersson, E.-M., Almquist, J., et al. (2019) · The Lancet Rheumatology · doi:10.1016/s2665-9913(19)30103-1 · Cited by 32
Góralska, J., Raźny, U., Polus, A., Dziewońska, A., Gruca, A., Zdzienicka, A., Dembinska-Kiec, A., Solnica, B., Micek, A., Kapusta, M., et al. (2020) · Nutrients · doi:10.3390/nu12020476 · Cited by 26
“GIP receptor down-regulation and desensitization have been suggested as potential causes of the diminished insulin response to GIP in T2D [11,12].”
BackgroundKolic, J., Spigelman, A. F., Smith, A. M., Fox, J. E. M., & MacDonald, P. E. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.577510 · Cited by 27
“Type 2 diabetes and metabolic syndrome are associated with disturbances in the incretin-signaling pathway (10, 11).”
BackgroundLong-Acting GLP-1 Analogs for the Treatment of Type 2 Diabetes Mellitus
Vilsbøll, T., & Knop, F. K. (2008) · BioDrugs · doi:10.2165/00063030-200822040-00004 · Cited by 25
Exenatide: first-in-class incretin mimetic for the treatment of Type 2 diabetes mellitus
Triplitt, C., & DeFronzo, R. A. (2006) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.1.3.329 · Cited by 25
Exenatide Use in the Management of Type 2 Diabetes Mellitus
Kyriacou, A., & Ahmed, A. B. (2010) · Pharmaceuticals · doi:10.3390/ph3082554 · Cited by 28
Exenatide: a novel treatment of Type 2 diabetes
Åhrén, B. (2005) · Therapy · doi:10.2217/14750708.2.2.207 · Cited by 26
“These hormones contribute to more than 70% of the insulin response after meal ingestion [26].”
BackgroundThe incretin effect in obese adolescents with and without type 2 diabetes: impaired or intact?
Aulinger, B. A., Vahl, T. P., Prigeon, R. L., D'Alessio, D. A., & Elder, D. A. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00496.2015 · Cited by 24
Mize, D. L. E., & Salehi, M. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0377-9 · Cited by 24
Oxyntomodulin May Distinguish New-Onset Diabetes After Acute Pancreatitis From Type 2 Diabetes
Bharmal, S. H., Cho, J., Stuart, C. E., Ramos, G. C. A., Ko, J., & Petrov, M. S. (2020) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000132 · Cited by 24
Bulum, T. (2022) · Biomedicines · doi:10.3390/biomedicines10102586 · Cited by 31
“In patients with type 2 diabetes (T2DM), the incretin effect is diminished or completely lost [4].”
BackgroundSitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes
Florentin, M., Liberopoulos, E. N., Mikhailidis, D. P., & Elisaf, M. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.10.1705 · Cited by 25
“The latter is either greatly impaired or even absent in patients with diabetes [21] due to a reduction in GLP-1 secretion and in pancreatic response to glucosedependent insulinotropic peptide [22,23] .”
BackgroundIncreased Incretin But Not Insulin Response after Oral versus Intravenous Branched Chain Amino Acids
Gojda, J., Straková, R., Plíhalová, A., Tůma, P., Potočková, J., Polak, J., & Anděl, M. (2017) · Annals of Nutrition and Metabolism · doi:10.1159/000475604 · Cited by 25
Ho, H., Shirakawa, H., Hirahara, K., Sone, H., Kamiyama, S., & Komai, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081995 · Cited by 25
Advances in the management of diabetes: therapies for type 2 diabetes
Tsoutsouki, J., Wunna, W., Chowdhury, A., & Chowdhury, T. A. (2020) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2019-137404 · Cited by 31
Shuai, H., Xu, Y., Ahooghalandari, P., & Tengholm, A. (2021) · Acta Physiologica · doi:10.1111/apha.13611 · Cited by 26
Update: vildagliptin for the treatment of Type 2 diabetes
Garber, A. J., & Sharma, M. D. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.1.105 · Cited by 26
“The same team of investigators also showed that the normal incretin effect is impaired in Type 2 diabetes [9] .”
BackgroundJepeal, L. I., Boylan, M. O., & Wolfe, M. M. (2003) · Regulatory Peptides · doi:10.1016/s0167-0115(03)00046-6 · Cited by 25
Kruszynska, Y. T., Ghatei, M. A., Bloom, S. R., & McIntyre, N. (1995) · Hepatology · doi:10.1002/hep.1840210408 · Cited by 28
Nielsen, S. T., Lehrskov‐Schmidt, L., Krogh‐Madsen, R., Solomon, T. P. J., Lehrskov‐Schmidt, L., Holst, J. J., & Møller, K. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2441 · Cited by 24
Gut-Based Strategies to Reduce Postprandial Glycaemia in Type 2 Diabetes
Kamruzzaman, M., Horowitz, M., Jones, K. L., & Marathe, C. S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.661877 · Cited by 24
“A seminal observation was the recognition that the incretin effect is markedly reduced in type 2 diabetes (31).”
BackgroundRecent advances in new-onset diabetes mellitus after kidney transplantation
Montada-Atin, T., & Prasad, G. V. R. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i5.541 · Cited by 24
Giugliano, D., Standl, E., Vilsbøll, T., Betteridge, J. D., Bonadonna, R. C., Campbell, I. W., Schernthaner, G.-H., Staels, B., Trichopoulou, A. D., & Farinaro, E. (2009) · Acta Diabetologica · doi:10.1007/s00592-009-0134-3 · Cited by 26
“The incretin effect is reduced in patients with type 2 diabetes [39].”
BackgroundThe role of incretins in cardiovascular control
Mafong, D. D., & Henry, R. R. (2009) · Current Hypertension Reports · doi:10.1007/s11906-009-0005-x · Cited by 24
Bariatric surgery and T2DM improvement mechanisms: a mathematical model
Toghaw, P., Matone, A., Lenbury, Y., & Gaetano, A. D. (2012) · Theoretical Biology and Medical Modelling · doi:10.1186/1742-4682-9-16 · Cited by 28
“In T2DM patients the “incretin effect” is reduced and this may depend on a defect in GLP-1 and GIP secretion [35].”
BackgroundDar, S., Tahrani, A. A., & Piya, M. K. (2015) · Practical Diabetes · doi:10.1002/pdi.1978 · Cited by 28
Albiglutide: a unique GLP-1 receptor agonist
Rendell, M. S. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1240780 · Cited by 23
“Diabetes is characterized by a reduced incretin effect, undoubtedly contributing to the inappropriate insulin secretion that characterizes the disease [17].”
BackgroundWongkrasant, P., Pongkorpsakol, P., Chitwattananont, S., Satianrapapong, W., Tuangkijkul, N., & Muanprasat, C. (2020) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2020.03.001 · Cited by 25
Lencioni, C., Resi, V., Romero, F., Lupi, R., Volpe, L., Bertolotto, A., Ghio, A., Prato, S. D., Marchetti, P., & Cianni, G. D. (2011) · PubMed · doi:10.3275/7799 · Cited by 23
Incretin-based therapies: new treatments for type 2 diabetes in the new millennium
Horowitz, M. (2009) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s4975 · Cited by 25
“17 However, in T2DM patients, the insulin response to oral glucose is blunted in comparison to non‑diabetic control subjects, 18 suggesting impairment of the incretin effect.”
Chowdhury, S., Wang, S., Patterson, B. W., Reeds, D. N., & Wice, B. M. (2013) · Regulatory Peptides · doi:10.1016/j.regpep.2013.10.003 · Cited by 24
“It has been known for many years that the incretin response, but not incretin release, is blunted in humans with T2DM [6,7].”
Meng, X., Xu, H., Zhang, Z., Fawcett, J. P., Li, J., Yang, Y., & Gu, J. (2017) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-017-0431-6 · Cited by 23
“Native human GLP-1 has an extremely short half-life of approximately 2 min due to its degradation by dipeptidyl peptidase (DPP)-4 [1].”
BackgroundMind over metabolism: The cephalic phase in relation to non-insulin-dependent diabetes and obesity☆
Storlien, L. H., & Bruce, D. G. (1989) · Biological Psychology · doi:10.1016/0301-0511(89)90108-7 · Cited by 23
Exploring Treatment Strategies for Type 2 Diabetes
Bloomgarden, Z. T. (2007) · Diabetes Care · doi:10.2337/dc07-zb10 · Cited by 28
“Creutzfeld and Nauck performed a classic experiment demonstrating this two decades ago, with a graded glucose infusion to give identical plasma glucose levels to that seen with oral glucose leading to an insulin response only one-quarter as great (41).”
BackgroundYamanouchi, D. (2025) · doi:10.20944/preprints202511.1408.v2 · Cited by 23
Loss of the Incretin Effect in Type 2 Diabetes: A Systematic Review and Meta-analysis
Grespan, E., Guolo, A., Muscelli, E., Ferrannini, E., & Mari, A. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac213 · Cited by 26
Rabbani, N., & Thornalley, P. J. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111905 · Cited by 25
Unger, J. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0470 · Cited by 23
“The impaired incretin effect in patients with type 2 DM occurs in the presence of normal GIP secretion, suggesting a possible loss of β-cell sensitivity to the insulinotropic effects of GIP in type 2 DM in addition to hyposecretion or decreased sensitivity to incretin factors.(20) The incretin defect in patients with…”
BackgroundPostpartum reversibility of impaired incretin effect in gestational diabetes mellitus
Kosiński, M., Knop, F. K., Vedtofte, L., Grycewiczv, J., Swierzewska, P., Cypryk, K., & Vilsbøll, T. (2013) · Regulatory Peptides · doi:10.1016/j.regpep.2013.08.002 · Cited by 25
Patel, S., Mace, O. J., Tough, I. R., White, J. R., Cock, T., Berglund, U. W., Schindler, M., & Cox, H. M. (2014) · International Journal of Obesity · doi:10.1038/ijo.2014.10 · Cited by 24
Frost, F. J., Jones, G. H., Dyce, P., Jackson, V., Nazareth, D. S., & Walshaw, M. J. (2019) · Diabetic Medicine · doi:10.1111/dme.14121 · Cited by 25
Incretin-based therapies in type 2 diabetes: A review of clinical results
Bosi, E., Lucotti, P., Setola, E., Monti, L. D., & Piatti, P. M. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.10.003 · Cited by 27
“In T2D the incretin pathway appears to be relatively deficient [14], especially in its GLP-1 component [16].”
BackgroundDeFronzo, R. A., Triplitt, & Cersosimo (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s4852 · Cited by 27
Metadata
- Authors
- Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W.
- ORCID
- Nauck, M.
- Venue
- Diabetologia
- Published
- 1986-01
- Volume
- 29
- Issue
- 1
- Pages
- 46-52
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2054564814
- Cited by
- 1,307
- References
- 40
- Citations by year
- 2026: 20 · 2025: 34 · 2024: 45 · 2023: 38 · 2022: 53 · 2021: 46 · 2020: 44 · 2019: 60 · 2018: 41 · 2017: 47 · 2016: 65 · 2015: 63 · 2014: 82 · 2013: 86 · 2012: 74
- FWCI
- 4.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, incretin effect, insulin secretion, C-peptide, glucose-dependent insulinotropic polypeptide, oral glucose tolerance, intravenous glucose infusion, hepatic insulin extraction, immunoreactive insulin
- MeSH terms
- Adult, Aged, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 2, Female, Gastric Inhibitory Polypeptide, Glucose, Glucose Tolerance Test, Humans, Infusions, Parenteral, Insulin, Male, Middle Aged, Pancreas
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.